CN1613012A - 可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记 - Google Patents

可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记 Download PDF

Info

Publication number
CN1613012A
CN1613012A CNA028267117A CN02826711A CN1613012A CN 1613012 A CN1613012 A CN 1613012A CN A028267117 A CNA028267117 A CN A028267117A CN 02826711 A CN02826711 A CN 02826711A CN 1613012 A CN1613012 A CN 1613012A
Authority
CN
China
Prior art keywords
described method
reagent
scd40l
experimenter
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028267117A
Other languages
English (en)
Chinese (zh)
Inventor
尤韦·施罗恩贝克
保罗·M·芮德克
彼得·利比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of CN1613012A publication Critical patent/CN1613012A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028267117A 2001-11-05 2002-11-05 可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记 Pending CN1613012A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33884101P 2001-11-05 2001-11-05
US60/338,841 2001-11-05

Publications (1)

Publication Number Publication Date
CN1613012A true CN1613012A (zh) 2005-05-04

Family

ID=23326383

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028267117A Pending CN1613012A (zh) 2001-11-05 2002-11-05 可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记

Country Status (7)

Country Link
US (2) US7189518B2 (https=)
EP (1) EP1451577A4 (https=)
JP (1) JP2005515407A (https=)
KR (1) KR20040068544A (https=)
CN (1) CN1613012A (https=)
CA (1) CA2464531A1 (https=)
WO (1) WO2003040691A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103163295A (zh) * 2011-12-08 2013-06-19 吴宗贵 一种用于急性冠脉综合征的液相芯片试剂盒以其制备方法
CN108196072A (zh) * 2007-11-05 2018-06-22 北欧生物科技公司 用于进行cvd风险评估的生物化学标志物

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727102B1 (en) * 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002018324A2 (en) 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
US7642286B2 (en) * 2001-06-21 2010-01-05 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions containing pravastatin
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
JP2005515407A (ja) * 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ATE394679T1 (de) * 2002-11-16 2008-05-15 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
WO2005110422A2 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
DE102004028303A1 (de) 2004-06-11 2005-12-29 Roche Diagnostics Gmbh Verfahren und Vorrichtung zum Nachweis von Analyten
EP1615035B1 (en) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Multimarker panel for diabetes type 1 and 2
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US7560227B2 (en) * 2005-02-28 2009-07-14 University Of Massachusetts Biomarkers of vulnerable atherosclerotic plaques and methods of use
WO2007042778A2 (en) * 2005-10-11 2007-04-19 St George's Enterprises Limited Monitoring cardiovascular disease by determining the expression of kir2ds2 and/or dap12
EP2431746A1 (en) 2005-11-17 2012-03-21 Biogen Idec MA Inc. Platelet aggregation assays
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
US20120034629A1 (en) * 2007-08-17 2012-02-09 Siemens Healthcare Diagnostics Inc. Prediction of non-fatal and fatal atherothrombotic events
AU2010324544A1 (en) 2009-11-27 2012-06-21 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
JP5857312B2 (ja) * 2011-08-11 2016-02-10 積水メディカル株式会社 心疾患診断マーカー
MX382403B (es) * 2012-08-16 2025-03-13 Critical Care Diagnostics Inc Métodos para predecir el riesgo de desarrollar hipertensión.
EP2968292A4 (en) * 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
ES3031007T3 (en) * 2017-11-10 2025-07-03 Op T Llc Peptide for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
JP7584125B2 (ja) 2020-11-02 2024-11-15 国立大学法人千葉大学 心血管イベントの発症リスクの検査方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358844A (en) * 1993-02-18 1994-10-25 Brigham And Women's Hospital, Inc. Preservation of blood platelets
US5622867A (en) * 1994-10-19 1997-04-22 Lifecell Corporation Prolonged preservation of blood platelets
US5919614A (en) * 1994-10-19 1999-07-06 Lifecell Corporation Composition comprising three platelet lesion inhibitors for platelet storage
WO1998020155A1 (en) * 1996-11-08 1998-05-14 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Diagnostic methods using cd40 ligand assay
ATE530180T1 (de) 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
JP2005515407A (ja) * 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108196072A (zh) * 2007-11-05 2018-06-22 北欧生物科技公司 用于进行cvd风险评估的生物化学标志物
CN103163295A (zh) * 2011-12-08 2013-06-19 吴宗贵 一种用于急性冠脉综合征的液相芯片试剂盒以其制备方法
CN103163295B (zh) * 2011-12-08 2015-11-18 吴宗贵 一种用于急性冠脉综合征的液相芯片试剂盒以其制备方法

Also Published As

Publication number Publication date
US7189518B2 (en) 2007-03-13
WO2003040691A3 (en) 2003-11-13
EP1451577A4 (en) 2006-03-15
US20080058360A1 (en) 2008-03-06
US20030152566A1 (en) 2003-08-14
KR20040068544A (ko) 2004-07-31
WO2003040691A2 (en) 2003-05-15
CA2464531A1 (en) 2003-05-15
JP2005515407A (ja) 2005-05-26
EP1451577A2 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
CN1613012A (zh) 可溶的cd40l(cd154)作为动脉粥样硬化的疾病的先兆标记
JP5094793B2 (ja) 心血管疾患マーカーおよび治療標的としてのｉｌ１ｒｌ−１
JP5661269B2 (ja) 真性糖尿病の検出および予防のための炎症性マーカー
CN103796669B (zh) 治疗心血管疾病和预测运动疗法功效的方法
JP2003508453A (ja) アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー
CA2680413A1 (en) Use of gelsolin to diagnose and treat rheumatoid arthritis
Naiya et al. Contribution of the arterial cells to atherosclerosis and plaque formation
Sheremeta et al. Prostaglandins in the inflamed central nervous system: potential therapeutic targets
JP2008516243A (ja) 治療後の全身炎症性マーカーの達成レベルの関連性
US20170343464A1 (en) System and method for assessing quantities or sizes of lipoprotein particles from lipoprotein particle compositions
Ohtsuka et al. Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy
WO2003088811A2 (en) Gelsolin as a prognostic marker of artherosclerotic diseases
US20240377399A1 (en) Compositions and methods for modulating hydroxylation of acc2 by phd3
CN120290711A (zh) Nfam1在制备评估冠心病风险试剂盒中的应用
AU2013202205B2 (en) Use of Gelsolin to Diagnose and Treat Inflammatory Disease
AU2002343620A1 (en) Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases
Tran et al. The Vascular Consequences of Metabolic Syndrome: Rodent Models
Ngan Jung Eun Park1, Gnanasekaran JebaMercy1, Kalailingam Pazhanchamy1, Xue Guo1, SoFong
Arafah Studies investigating the impact of select genotypes on the pharmacological effect of fenofibrate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned